265 related articles for article (PubMed ID: 38364355)
1. Targeting myeloma metabolism: How abnormal metabolism contributes to multiple myeloma progression and resistance to proteasome inhibitors.
Zhou X; He R; Hu WX; Luo S; Hu J
Neoplasia; 2024 Apr; 50():100974. PubMed ID: 38364355
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibition in multiple myeloma: lessons for other cancers.
Saavedra-García P; Martini F; Auner HW
Am J Physiol Cell Physiol; 2020 Mar; 318(3):C451-C462. PubMed ID: 31875696
[TBL] [Abstract][Full Text] [Related]
3. Targeting lipid metabolism in multiple myeloma cells: Rational development of a synergistic strategy with proteasome inhibitors.
Xu G; Huang S; Peng J; Gao X; Li M; Yu S; Liu Z; Qie P; Wang Y; Yu S; Liu S; Wen H; Su L; Li P; Guang B; Dong R; Liu J; Yang T
Br J Pharmacol; 2021 Dec; 178(23):4741-4757. PubMed ID: 34378191
[TBL] [Abstract][Full Text] [Related]
4. Combined inhibition of p97 and the proteasome causes lethal disruption of the secretory apparatus in multiple myeloma cells.
Auner HW; Moody AM; Ward TH; Kraus M; Milan E; May P; Chaidos A; Driessen C; Cenci S; Dazzi F; Rahemtulla A; Apperley JF; Karadimitris A; Dillon N
PLoS One; 2013; 8(9):e74415. PubMed ID: 24069311
[TBL] [Abstract][Full Text] [Related]
5. Proteasome inhibitors for multiple myeloma.
Okazuka K; Ishida T
Jpn J Clin Oncol; 2018 Sep; 48(9):785-793. PubMed ID: 30102324
[TBL] [Abstract][Full Text] [Related]
6. Targeting autophagy increases the efficacy of proteasome inhibitor treatment in multiple myeloma by induction of apoptosis and activation of JNK.
Salimi A; Schroeder KM; Schemionek-Reinders M; Vieri M; Maletzke S; Gezer D; Masouleh BK; Appelmann I
BMC Cancer; 2022 Jul; 22(1):735. PubMed ID: 35790913
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors.
Tagoug I; Jordheim LP; Herveau S; Matera EL; Huber AL; Chettab K; Manié S; Dumontet C
Clin Cancer Res; 2013 Jul; 19(13):3556-66. PubMed ID: 23674497
[TBL] [Abstract][Full Text] [Related]
8. Multiple myeloma metabolism - a treasure trove of therapeutic targets?
Roman-Trufero M; Auner HW; Edwards CM
Front Immunol; 2022; 13():897862. PubMed ID: 36072593
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors.
Prelowska MK; Mehlich D; Ugurlu MT; Kedzierska H; Cwiek A; Kosnik A; Kaminska K; Marusiak AA; Nowis D
Cancer Lett; 2021 Jun; 507():13-25. PubMed ID: 33713737
[TBL] [Abstract][Full Text] [Related]
10. The proteasome and proteasome inhibitors in multiple myeloma.
Gandolfi S; Laubach JP; Hideshima T; Chauhan D; Anderson KC; Richardson PG
Cancer Metastasis Rev; 2017 Dec; 36(4):561-584. PubMed ID: 29196868
[TBL] [Abstract][Full Text] [Related]
11. Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma.
Ferguson ID; Lin YT; Lam C; Shao H; Tharp KM; Hale M; Kasap C; Mariano MC; Kishishita A; Patiño Escobar B; Mandal K; Steri V; Wang D; Phojanakong P; Tuomivaara ST; Hann B; Driessen C; Van Ness B; Gestwicki JE; Wiita AP
Cell Chem Biol; 2022 Aug; 29(8):1288-1302.e7. PubMed ID: 35853457
[TBL] [Abstract][Full Text] [Related]
12. Multiple myeloma cells are exceptionally sensitive to heat shock, which overwhelms their proteostasis network and induces apoptosis.
Sha Z; Goldberg AL
Proc Natl Acad Sci U S A; 2020 Sep; 117(35):21588-21597. PubMed ID: 32817432
[TBL] [Abstract][Full Text] [Related]
13. Resistance to proteasome inhibitors and other targeted therapies in myeloma.
Wallington-Beddoe CT; Sobieraj-Teague M; Kuss BJ; Pitson SM
Br J Haematol; 2018 Jul; 182(1):11-28. PubMed ID: 29676460
[TBL] [Abstract][Full Text] [Related]
14. Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma.
Ettari R; Zappalà M; Grasso S; Musolino C; Innao V; Allegra A
Pharmacol Ther; 2018 Feb; 182():176-192. PubMed ID: 28911826
[TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibitors: introduction.
Heuck CJ; Shaughnessy JD
Semin Hematol; 2012 Jul; 49(3):193-5. PubMed ID: 22726541
[No Abstract] [Full Text] [Related]
16. Biologic impact of proteasome inhibition in multiple myeloma cells--from the aspects of preclinical studies.
Hideshima T; Anderson KC
Semin Hematol; 2012 Jul; 49(3):223-7. PubMed ID: 22726545
[TBL] [Abstract][Full Text] [Related]
17. A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells.
Milan E; Perini T; Resnati M; Orfanelli U; Oliva L; Raimondi A; Cascio P; Bachi A; Marcatti M; Ciceri F; Cenci S
Autophagy; 2015; 11(7):1161-78. PubMed ID: 26043024
[TBL] [Abstract][Full Text] [Related]
18. Lessons Learned from Proteasome Inhibitors, the Paradigm for Targeting Protein Homeostasis in Cancer.
Kambhampati S; Wiita AP
Adv Exp Med Biol; 2020; 1243():147-162. PubMed ID: 32297217
[TBL] [Abstract][Full Text] [Related]
19. Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition.
Bennett MK; Li M; Tea MN; Pitman MR; Toubia J; Wang PP; Anderson D; Creek DJ; Orlowski RZ; Gliddon BL; Powell JA; Wallington-Beddoe CT; Pitson SM
Neoplasia; 2022 Jan; 24(1):1-11. PubMed ID: 34826777
[TBL] [Abstract][Full Text] [Related]
20. Entinostat-Bortezomib Hybrids against Multiple Myeloma.
Ferro A; Graikioti D; Gezer E; Athanassopoulos CM; Cuendet M
Molecules; 2023 Feb; 28(3):. PubMed ID: 36771118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
